To the Editor We agree with Drs Rodriguez-Gutierrez and McCoy that improving lives of people with type 2 diabetes is more important than improving their laboratory numbers.1 We disagree with their statement that variation in study end points in cardiovascular outcome trials can be attributed to the study drugs rather than the benefit of reduction in hemoglobin A1c (HbA1c) level.
Giugliano D, Maiorino MI, Esposito K. Measuring the Quality of Diabetes Care. JAMA. 2019;322(12):1212. doi:10.1001/jama.2019.11136
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: